Wall Street analysts expect Inovio Pharmaceuticals Inc. (NASDAQ: INO) to post revenue of $ 2.69 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have released Inovio Pharmaceuticals' earnings estimates, with the highest estimate of sales being $ 5.15 million, the lowest estimate being $ 1.05 million. Inovio Pharmaceuticals recorded revenues of $ 8.79 million for the same period last year, which would mean a negative year-on-year growth of 69.4%. The company is due to announce the next income report on Wednesday, March 13.
According to Zacks, analysts expect Inovio Pharmaceuticals to report worldwide sales of $ 30.88 million for the current business year, with estimates ranging from $ 28.10 million to $ 35.28 million. For the next financial year, analysts expect the company to report revenue of $ 22.86 million, with estimates ranging from $ 4.20 million to $ 34.78 million. Zacks' sales calculations are based on a survey of sales research analysts that provide coverage to Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ: INO) released its quarterly results on Thursday 8 November. The biopharmaceutical company reported ($ 0.27) earnings per share for the quarter to reach a consensus estimate of $ 0.05 ($ 0.32). Inovio Pharmaceuticals had a negative net margin of 232.58% and a negative return on equity of 69.89%. The company had sales of $ 2 million over the quarter, compared to analysts' expectations of $ 2.20 million. During the same period last year, EPS acquired EPS (US $ 0.39).
INO has been the subject of several analysts' reports. Maxim re-issued the buy-in rating and on Thursday, August 16, it issued a target price of $ 8.00 for Inovio Pharmaceuticals. HC Wainwright set a target price of $ 13.00 for Inovio Pharmaceuticals, and on Wednesday, August 15, he provided the "buy" rating in a research report. BidaskClub raised Inovio Pharmaceuticals shares from "hold" to "buy" rating in a research report Wednesday, September 12th. Stifel Nicolaus began covering Inovio Pharmaceuticals' stake in a research report Tuesday, 2 October. They issued a "buy" rating and a target price of $ 8.00 per company. ValuEngine eventually increased Inovio Pharmaceuticals's stake in the "buy" rating on the "buy" rating on Saturday's research report. One of the stock research analysts evaluated the stock by selling a rating, one issued a rating and 5 shares rated. The company has an average "buy" rating and an average target price of $ 10.75.
In other reports of Inovio Pharmaceuticals, CEO Jong Joseph Kim sold 49,060 shares of the company's shares in a transaction on Wednesday, September 12. Shares were sold at an average price of $ 5.37 for a total transaction of $ 263,452.20. Upon completion of the sale, the Chief Executive Officer currently has 2 357 554 shares of the Company's shares valued at approximately USD 12 660 064.98. This sale was published in a legal tender at the Securities and Exchange Commission, which is available on the SEC's website. The owners own 9.40% of the company's shares.
A number of institutional investors have recently changed their position in the INO. UBS Group AG raised its stake in Inovio Pharmaceuticals by 156.7% in the first quarter. UBS Group AG now owns 442,893 shares of a biopharmaceutical company fund worth USD 2,086,000 after buying another 270,373 shares in the last quarter. Guggenheim Capital LLC earned a new share of $ 2,375,000 in Inovio Pharmaceuticals in the first quarter. Emerald Advisers Inc. acquired a new stake in Inovio Pharmaceuticals during the second quarter, worth $ 228,000. Connor Clark and Lunn Investment Management Ltd. in the second quarter, it raised its stake in Inovio Pharmaceuticals by 50.2%. Connor Clark and Lunn Investment Management Ltd. now owns 101,225 shares of a biopharmaceutical company worth $ 397,000 after buying 33,825 shares in the last quarter. Finally, Wasatch Advisors Inc. during the second quarter, canceled its stake in Inovio Pharmaceuticals by 6.8%. Wasatch Advisors Inc. now owns 2 738 190 shares of a biopharmaceutical company, worth $ 10,734,000, after buying 174,911 shares in the last quarter. 31.71% of shares are held by institutional investors and hedge funds.
NASDAQ shares: On Thursday, INO traded at $ 0.10 during lunch deals and attacked US $ 5.29. The assets had a volume of trades of 1,937,670 shares compared to an average of 885,917 shares. Inovio Pharmaceuticals has a 12-month minimum of $ 3.64 and a 12-month maximum of $ 6.30.
Inovio Pharmaceuticals' profile
Inovio Pharmaceuticals, Inc., a clinical biopharmaceutical company, is developing active immunotherapy for DNA and vaccines to prevent and treat cancer and infectious diseases. His SynCon immunotherapy has the ability to interrupt tolerance of the immune system of cancer cells and to facilitate protection against cross-infection against known and new unsustainable strains of pathogens such as influenza.
Recommended story: Split Split
Get a free copy of Zacks' research report about Inovio Pharmaceuticals (INO)
For more information on Zacks Investment Research's research offers, visit Zacks.com
Get news and ratings for Inovio Pharmaceuticals Daily – Enter your e-mail address below to get a brief daily summary of Inovio Pharmaceuticals 'latest analysts' and analyst reports and a company associated with MarketBeat.com e-mail newsletter for FREE.